ARGX vs. BIO: argenx vs. Bio-Rad Laboratories Stock Comparison

November 11, 2026

How do argenx (ARGX) and Bio-Rad Laboratories (BIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

argenx (ARGX) and Bio-Rad Laboratories (BIO) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while BIO is classified in Life Sciences Tools & Services.

Bio-Rad Laboratories (BIO) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Profile Item	ARGX	BIO
Name	argenx SE American Depositary Receipt	Bio-Rad Laboratories Inc.
Country/Region	Netherlands	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	58.31 billion USD	10.26 billion USD
Currency	USD	USD
Exchange	Nasdaq	NYSE
Listing Date	May 18, 2017	February 27, 1980
Security Type	ADR	Common Stock

Price Performance

Cumulative Growth

ARGX

BIO

GSPC

argenx (ARGX) vs. Bio-Rad Laboratories (BIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for argenx (ARGX) and Bio-Rad Laboratories (BIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for argenx (ARGX) and Bio-Rad Laboratories (BIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
Total Return (1Y)	11.91%	28.31%
Total Return (3Y, Annualized)	25.68%	8.52%
Total Return (5Y, Annualized)	24.22%	-11.74%

Risk Profile

Drawdown History

ARGX

BIO

GSPC

argenx (ARGX) vs. Bio-Rad Laboratories (BIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for argenx (ARGX) and Bio-Rad Laboratories (BIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
Volatility (1Y, Annualized)	37.87%	36.50%
Beta (5Y)	0.45	1.03
Max Drawdown (5Y)	-38.20%	-72.24%
Avg. Volume (3M)	359.84K	250.78K

Risk-Adjusted Performance

Risk-Return Positioning

ARGX and BIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
Sharpe Ratio (1Y)	0.20	0.66
Sortino Ratio (1Y)	0.31	0.98

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Bio-Rad Laboratories (BIO) earns 14.27% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ARGX: --

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max: 109.18%
BIO: 14.27%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): ARGX does not report ROE, so it has no value marker; BIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Both argenx (ARGX) at 31.73% and Bio-Rad Laboratories (BIO) at 39.45% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.73%

ARGX: 31.73%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO: 39.45%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

argenx (ARGX) at 36.27% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO) at 11.82%, which runs around its industry’s norm.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

36.27%

Max: 83.12%
ARGX: 36.27%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.82%

Max: 83.12%
Q3: 14.77%
BIO: 11.82%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
ROE (TTM)	--	14.27%
ROA (TTM)	--	1.50%
Net Margin (TTM)	31.73%	39.45%
Operating Margin (TTM)	36.27%	11.82%
Gross Margin (TTM)	59.84%	52.19%

Growth

Revenue Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Bio-Rad Laboratories (BIO) at 0.65% is closer to the peer norm — faster top-line expansion for ARGX.

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Bio-Rad Laboratories (BIO) has no EPS growth figure this period.

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
Revenue Growth (YoY)	89.64%	0.65%
Revenue Growth (3Y CAGR)	116.25%	-2.68%
EPS Growth (YoY)	53.13%	--
EPS Growth (3Y CAGR)	--	--

Financial Strength

Current Ratio (MRQ)

Short-term liquidity can only be read on one side of this pairing: Bio-Rad Laboratories (BIO) shows current ratio of 3.18 against its industry benchmark, while argenx (ARGX) has no reading this period.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
Min: 0.10
ARGX: --

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max: 25.13
Q3: 12.13
Median: 5.52
BIO: 3.18
Q1: 2.47
Min: 0.10

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): ARGX does not report current ratio, so it has no value marker; BIO is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Debt / Equity (MRQ)

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Bio-Rad Laboratories (BIO) at 0.18 runs a more typical debt-to-equity mix.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.01

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
ARGX: 0.01
Min: 0.00

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max: 1.42
Q3: 0.65
BIO: 0.18
Median: 0.15
Q1: 0.02
Min: 0.00

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
Current Ratio (MRQ)	--	3.18
Debt / Equity (MRQ)	0.01	0.18
Net Debt / EBITDA	-2.70	-0.73

Dividends

Dividend Yield (TTM)

Neither argenx (ARGX) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither argenx (ARGX) nor Bio-Rad Laboratories (BIO) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ARGX: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO) at 10.14 sits in the cheaper P/E ratio quartile, while argenx (ARGX) at 32.12 is closer to its industry’s usual earnings multiple — a discount for BIO, though growth and earnings durability still matter.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

32.12

Max: 85.34
Q3: 43.46
ARGX: 32.12
Median: 26.69
Q1: 13.30
Min: 0.07

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.14

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
BIO: 10.14
Min: 0.07

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both argenx (ARGX) at 9.86 and Bio-Rad Laboratories (BIO) at 3.96 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.86

Max: 58.18
Q3: 25.77
ARGX: 9.86
Median: 7.30
Q1: 3.01
Min: 0.01

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.96

Max: 58.18
Q3: 25.77
Median: 7.30
BIO: 3.96
Q1: 3.01
Min: 0.01

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO) at 1.35 sits in the lower P/B ratio quartile relative to book while argenx (ARGX) at 172.23 prices above its industry range — a wide valuation gap against assets.

ARGX

Pharmaceuticals, Biotechnology & Life Sciences industry group

172.23

ARGX: 172.23
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

BIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.35

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
BIO: 1.35
Min: -5.59

argenx (ARGX) vs. Bio-Rad Laboratories (BIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for argenx (ARGX) and Bio-Rad Laboratories (BIO)
Metric	ARGX	BIO
P/E Ratio (TTM)	32.12	10.14
P/S Ratio (TTM)	9.86	3.96
P/B Ratio (MRQ)	172.23	1.35
Free Cash Flow Yield (TTM)	--	2.65%